Free Trial
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Arcturus Therapeutics logo
$13.64 +0.02 (+0.11%)
As of 07/3/2025 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Key Stats

Today's Range
$13.44
$13.94
50-Day Range
$10.84
$14.41
52-Week Range
$8.04
$25.88
Volume
172,653 shs
Average Volume
421,236 shs
Market Capitalization
$369.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.00
Consensus Rating
Buy

Company Overview

Arcturus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

ARCT MarketRank™: 

Arcturus Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 718th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arcturus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arcturus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.22) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcturus Therapeutics is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcturus Therapeutics is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcturus Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Arcturus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    20.02% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Arcturus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Arcturus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.02% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Arcturus Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.60% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcturus Therapeutics' insider trading history.
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

ARCT Stock Analysis - Frequently Asked Questions

Arcturus Therapeutics' stock was trading at $16.97 at the beginning of 2025. Since then, ARCT stock has decreased by 19.7% and is now trading at $13.6350.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its earnings results on Monday, May, 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. The biotechnology company had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative trailing twelve-month return on equity of 27.41%.
Read the conference call transcript
.

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/12/2025
Today
7/04/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$54.00
High Stock Price Target
$70.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+296.0%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.94 million
Pretax Margin
-47.72%

Debt

Sales & Book Value

Annual Sales
$152.31 million
Price / Cash Flow
N/A
Book Value
$8.90 per share
Price / Book
1.53

Miscellaneous

Free Float
22,619,000
Market Cap
$369.78 million
Optionable
Optionable
Beta
2.27

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ARCT) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners